I would echo your statement that any non-compliance is a concern for any industry. I mean, there is a backbone of trust within our consumer base.
I think we would like to draw attention, though, to those three incidents. If we take the number of products on market, which Health Canada has claimed is 50,000, three out of that 50,000 is...we're talking about 0.006% that resulted in issues.
I don't believe that recategorizing and redefining a therapeutic product to bring natural health products in line with pharmaceuticals is the solution to that problem. As my colleague mentioned, would industry be open to discussions about recall powers that don't require this reset of definition? To put it on the record, yes, we would.
I think there could be other tools that could be used to bring those who stay non-compliant back in compliance. This is not the appropriate solution, because of the unintended consequences of that recategorization.